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Annual Mee ng: Specialty Workshops, Scien fic Assembly and Trade Show scheduled for January 11-16 which will be
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The presen ng author on this abstract needs to complete NAEMSP’s Presenta on Summary and Financial
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Background: Intranasal naloxone is commonly used by emergency medical services personnel to treat
prehospital opioid overdose. However, the optimal dose is unclear and currently no study exists
comparing the clinical effect of intranasal naloxone at different doses. Objective: The goal of this
investigation was to compare the safety, efficacy, and cost of 0.4 mg versus 2.0 mg intranasal naloxone
for prehospital treatment of presumed opioid overdose. Methods: A retrospective, cross-sectional
study was performed of two hundred eighteen (218) consecutive adult patients receiving intranasal
naloxone in either of two neighbouring counties in Southeast Michigan, USA: one that uses a 0.4 mg
protocol and one that uses a 2.0 mg protocol. The primary outcomes were response to initial dose,
requirement of additional dosing, and incidence of adverse effects. Unpooled, two-tailed, two-sample t-
tests and chi-squared tests for homogeneity were performed with statistical significance defined as p <
0.05. Results: There was no statistically significant difference between the two populations in age, mass,
gender, or proportion of known exposures identified as heroin. There was no statistically significant
difference in response to initial dose, requirement of redosing, or total number of doses by any route.
The overall rate of adverse effects was 2.1% under the lower dose protocol and 29.0% under the higher
dose protocol (p < 0.001). The lower dose protocol was 79% less costly. Conclusion: This study cannot
conclude whether the observed difference in rate of adverse effects was due to the difference in initial
dose or to a confounding factor such as differences in reporting. However, the observation that higher
total doses of naloxone carry greater risk of adverse effects is supported by previous investigations. In
this study, treatment of prehospital opioid overdose using intranasal naloxone at an initial dose of 0.4
mg was equally effective during the prehospital period as treatment at an initial dose of 2.0 mg, was
associated with a lower rate of adverse effects, and represented a substantial cost savings.
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